Deciphera Pharmaceuticals Inc (DCPH)
25.38
+0.01
(+0.04%)
USD |
NASDAQ |
May 07, 16:00
25.37
-0.01
(-0.04%)
After-Hours: 20:00
Deciphera Pharmaceuticals Research and Development Expense (Quarterly): 58.60M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 58.60M |
| September 30, 2023 | 62.46M |
| June 30, 2023 | 58.30M |
| March 31, 2023 | 54.76M |
| December 31, 2022 | 48.07M |
| September 30, 2022 | 47.48M |
| June 30, 2022 | 44.86M |
| March 31, 2022 | 47.41M |
| December 31, 2021 | 74.93M |
| September 30, 2021 | 66.44M |
| June 30, 2021 | 59.98M |
| March 31, 2021 | 55.68M |
| December 31, 2020 | 52.29M |
| September 30, 2020 | 49.21M |
| June 30, 2020 | 46.08M |
| Date | Value |
|---|---|
| March 31, 2020 | 51.39M |
| December 31, 2019 | 46.64M |
| September 30, 2019 | 40.37M |
| June 30, 2019 | 34.81M |
| March 31, 2019 | 35.79M |
| December 31, 2018 | 27.36M |
| September 30, 2018 | 20.63M |
| June 30, 2018 | 17.98M |
| March 31, 2018 | 16.92M |
| December 31, 2017 | 15.66M |
| September 30, 2017 | 9.751M |
| June 30, 2017 | 8.446M |
| March 31, 2017 | 5.659M |
| December 31, 2016 | 6.537M |
| September 30, 2016 | 4.717M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
34.81M
Minimum
Jun 2019
74.93M
Maximum
Dec 2021
52.62M
Average
51.39M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.695B |
| Dynavax Technologies Corp | 14.12M |
| Gilead Sciences Inc | 3.95B |
| Esperion Therapeutics Inc | 17.74M |
| SINTX Technologies Inc | 1.824M |